Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed gene therapy programs in GM1 gangliosidosis and Fragile X syndrome.
Ralph Laufer, PhD
Advertisement
Chief scientific officer, Lysogene
Articles by Ralph Laufer, PhD
Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed LYS-SAF302, its mechanism of action, trial data, and further research.
The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Activity Recap: November 2025 Features SMA Approval, Boxed Warning for Elevidys, and More
2
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal” With Anusha Kalbasi, MD
3
Karlla W. Brigatti, MS, CGC, on Accelerating SMA Diagnosis and Treatment
4
